ArticleStem cell research & therapy2015
A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance.
Article in Stem cell research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed.
- Sphingolipid Metabolism Links Morphological Signatures to Immunomodulatory Potency in Human Mesenchymal Stromal Cells.Cellular and molecular bioengineering · 2026Article
- Donor Pooling as an Effective Method to Increase MSC EV Production Without Compromising Therapeutic Potential.Journal of extracellular biology · 2026Article
- Development and validation of a potency assay matrix for optimized and consistent manufacture of clinical mesenchymal stem/stromal cells.Frontiers in immunology · 2026Article
- Stem Cell and Cell-Free Strategies for Osteoarthritis: Toward Durable Regenerative Therapies.Stem cells international · 2026Review
- Development of an in vitro method to assess the immunogenicity of biologics in the prevention of infectious diseases.Immunologic research · 2025Article
- Stem Cell Therapy in Ischemic Heart Failure.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025Review
- Pooling umbilical cord-mesenchymal stromal cells derived from selected multiple donors reduces donor-dependent variability and improves their immunomodulatory properties.Stem cell research & therapy · 2025Article
- Increasing robustness ofRegenerative therapy · 2025Article
- Stabilizing milk-derived extracellular vesicles (mEVs) through lyophilization: a novel trehalose and tryptophan formulation for maintaining structure and Bioactivity during long-term storage.Journal of biological engineering · 2025Article
- Stromal vascular fraction inhibits renal fibrosis by regulating metabolism and inflammation in obstructive nephropathy.Frontiers in pharmacology · 2025Article
- Advantages of pooling of human bone marrow-derived mesenchymal stromal cells from different donors versus single-donor MSCs.Scientific reports · 2024Article
- Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease.Nature medicine · 2024Article
- The Beneficial Effects of Mesenchymal Stem Cells in Acute Kidney Injury: A Narrative Review.Current stem cell research & therapy · 2024Review
- Powering prescription: Mitochondria as "Living Drugs" - Definition, clinical applications, and industry advancements.Pharmacological research · 2024Review
- The issue of heterogeneity of MSC-based advanced therapy medicinal products-a review.Frontiers in cell and developmental biology · 2024Review
- Evaluation of the Precision of Kinetic Stem Cell (KSC) Counting for Specific Quantification of Human Mesenchymal Stem Cells in Heterogeneous Tissue Cell Preparations.Life (Basel, Switzerland) · 2023Article
- Article
- Stromal vascular fraction in the treatment of myositis.Cell death discovery · 2023Review
- The Potential Use of THP-1, a Monocytic Leukemia Cell Line, to Predict Immune-Suppressive Potency of Human Bone-Marrow Stromal Cells (BMSCs) In Vitro: A Pilot Study.International journal of molecular sciences · 2023Article
- Liver Disease and Cell Therapy: Advances Made and Remaining Challenges.Stem cells (Dayton, Ohio) · 2023Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inherent immunomodulatory capacity of mesenchymal stem/progenitor cells (MSPCs) encouraged initiation of multiple clinical trials. Release criteria for therapeutic MSPCs cover identity, purity and safety but appropriate potency assessment is often missing. Reports on functional heterogeneity of MSPCs created additional uncertainty regarding donor and organ/source selection. We established a robust immunomodulation potency assay based on pooling responder leukocytes to minimize individual immune response variability. Comparing various MSPCs revealed significant potency inconsistency and generally diminished allo-immunosuppression compared to dose-dependent inhibition of mitogenesis. Gamma-irradiation to block unintended MSPC proliferation did not prohibit chondrogenesis and osteogenesis in vivo, indicating the need for alternative safety strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.